Efficacy and safety of pharmaceutical interventions in epicardial adipose tissue: A protocol for systematic review and network meta-analysis

Leonardo Roever1*, Elmiro Santos Resende1, Angelica Lemos Debs Diniz1, Nilson Penha-Silva1, João Lucas O’Connell1, Fernanda Rodrigues de Souza1, Poliana Rodrigues Alves Duarte1, Paulo Fernando Silva Gomes1, Hugo Ribeiro Zanetti1,2, Anaísa Silva Roerger-Borges2, Fernando César Veloso1, Thiago Montes Fidale3, Antonio Casella-Filho4, Paulo Magno Martins Dourado5, Antonio Carlos Palandrí Chagas6,8, Sadeq Ali-Hasan-Al-Saegh1, Paulo Eduardo Ocke Reis6, Rogério de Melo Costa Pinto7, Gustavo B F Oliveira7, Álvaro Avezum7, Mansueto Neto8, André Durães8, Rose Mary Ferreira Lisboa da Silva1, Antonio José Grande10, Celise Denardi11, Renato Delascio Lopes11, Nitesh Nerlekar11, Shahab Alizadeh11, Adrian V Hernandez11, Maria Inês da Rosa12, Gary Tse12, Tong Liu18, Michel Pompeu B O Sá19, Giuseppe Biondi-Zoccai20, for the Brazilian Network of Research in Meta-analysis (BRAMETIS)

1 Federal University of Uberlândia, Department of Clinical Research, Brazil
2 Heart Institute (InCor), Master Institute of Education President Antonio Carlos, IMEPAC, Araguari, Department of Clinical Research, Brazil
3 HCFMUSP- University of São Paulo Medical School, Department of Cardiology, São Paulo, Brazil
4 Faculty of Medicine ABC, Department of Cardiology, Santo André, Brazil
5 Cardiovascular Research Center, Shahid Sadoughi University of Medical Sciences, Department of Cardiology, Yazd, Iran
6 Department of Specialized and General Surgery, Fluminense Federal University, Rio de Janeiro, Brazil
7 Dante Pazzanese Institute of Cardiology, Department of Clinical Research, São Paulo, Brazil
8 Federal University of Minas Gerais, Department of Cardiology, MG, Brazil
9 Federal University of Mato Grosso do Sul, Department of Medicine, MT, Brazil
10 FOP Unicamp, Department of Clinical Research, SP, Brazil
11 Division of Cardiology, Duke University Medical Center, Department of Clinical Research, Durham, NC, USA
12 Monash Cardiovascular Research Centre and MonashHeart, Department of Cardiology, Clayton, Victoria, Australia
13 University of Connecticut/Hartford Hospital Evidence-Based Practice Center, Hartford, Department of Comparative Effectiveness and Outcomes Research, Health Outcomes, CT, USA
14 Laboratory of Epidemiology, University of Extremo Sul Catarinense, Criciúma, Brazil
15 Department of Medicine and Therapeutics and Li Ka Shing Institute of Health Sciences, Faculty of Medicine, Chinese University of Hong Kong, Hong Kong, China
16 Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardioiology, the Second Hospital of Tianjin Medical University, Tianjin, China
17 Division of Cardiovascular Surgery of Pronto Socorro Cardiológico de Pernambuco - PROCAPE. University of Pernambuco (UPE), Recife, PE, Brazil
18 Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Latina, Italy
19 Department of AngioCardioNeurology, IRCCS Neuroradio, Pozzilli, Italy

Abstract

Introduction: The excess of Epicardial adipose tissue (EAT) is a complex disease that includes endothelial dysfunction, insulin resistance, diabetes, hypertension, ectopic obesity, and dyslipidaemia and an increased risk of cardiovascular events. This study aims to fill this gap of research by conducting a Bayesian network meta-analysis to compare major drugs to treat EAT.

Methods and analysis: We will search the PubMed, EMBASE, Cochrane Library, Web of Science, Embase, google scholar, clinical trials registry (ClinicalTrials.gov) for unpublished or undergoing research listed in registry platforms. Randomized controlled trials (RCTs) on the drug therapy of EAT with outcome measures including diagnostic criteria of EAT will be included. The quality of included RCTs will be evaluated according to the Cochrane Collaboration’s risk of bias tool. Traditional pairwise meta-analysis and Bayesian network meta-analysis will be conducted to compare the efficacies of antidiabetic drugs. Sensitivity analysis on the sample size of RCTs, meta-regression analysis on the follow-up periods, dosages and baselines of outcome measure, contradiction analysis between pairwise and network meta-analyses, and publication bias analysis will be performed. Randomized controlled trials (RCTs) on the drug therapy of MetS with outcome measures criteria of MetS diagnostic will be included. The quality of included RCTs will be evaluated according to the Cochrane Collaboration’s risk of bias tool. Traditional pairwise meta-analysis and Bayesian network meta-analysis will be conducted to compare the efficacies of drugs. Sensitivity analysis on the sample size of RCTs, meta-regression analysis on the follow-up periods, dosages and baselines of outcome measure, contradiction analysis between pairwise and network meta-analyses, and publication bias analysis, will be performed.

*Correspondence to: Leonardo Roever, Federal University of Uberlândia, Department of Clinical Research, E-mail: leonardoroever@hotmail.com

Key words: drugs, epicardial fat, systematic review

Received: November 01, 2018; Accepted: November 12, 2018; Published: November 14, 2018
Abbreviations

CIs: Confidence Intervals; HDL: high-density lipoprotein; LDL: low-density lipoprotein; MD: mean difference; RR: risk ratio; WC: waist circumference; EAT: Epicardial adipose tissue; MetS: metabolic syndrome; CVD: cardiovascular disease; NMA: network meta-analysis; RCTs: randomized controlled trials

Strengths and limitations of this study

This systematic review and meta-analysis will offer better understanding regarding the association between drugs and EAT.

Included studies may have substantially different methodologies, which could limit our ability to draw reliable conclusions from the existing evidence base.

Depending on the results, confounding factors that were not adjusted for in the selected studies and low generalizability can be limitations. Individual patient data will not be available.

Background

Epicardial adipose tissue (EAT) is associated with endothelial dysfunction, insulin resistance, diabetes, hypertension, ectopic obesity, and dyslipidemia and an increased risk of cardiovascular disease and stroke [1-4]. It is in large part the result of unbalanced diet, low socioeconomic and cultural level, stress and sedentary lifestyle [3-8].

Currently, there is a lack of high quality evidence to support the tailoring of drugs to treatment regimens for EAT according to an individual’s characteristics or other treatment effect modifiers. As such, it is imperative to improve existing guideline recommendations and inform decision-makers about the safety and effectiveness of these interventions.

This study conducted a Bayesian NMA to compare the risk factors control efficacy of drugs use in EAT.

Objective

The objective of this study is to compare efficacies of drugs to reduce EAT by NAM on RCTs.

Methods/design

Design

Systematic review and Bayesian NMA. EAT is a deposit of visceral fat, located between the heart and the pericardium, which shares many of the pathophysiological properties of other visceral fat deposits, but with potential direct local effects in the inflammatory and coronary atherosclerotic process[9-11].

The study is registered with PROSPERO (CRD42018091437). This protocol conforms to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocols (PRISMA-P) guidelines [12-14].

Eligibility criteria

We will include randomized controlled trials (RCTs) comparing one drug with another drug as monotherapy or placebo for the treatment of TN. Quasi-randomized controlled trials allocating participants according to birth date or the consequences of enrolment will be excluded. The minimum duration for RCT inclusion will be set at 4 weeks. Trials with more than a two arm design will be considered only if the available data meet the criteria for an intervention. For trials with a crossover design, data will only be extracted from the first randomization period. The retrieved reports will be screened according to the checklist of eligibility and the eligibility criteria shown below including participants, interventions, controls, types of study and other criteria.

Patient and public involvement

The patients and/or the public are not involved; it is an article of protocol of systematic revision and network of meta-analysis.

Search strategy

The following databases will be searched from their inception forward for potentially eligible studies in English language published on or before 31 January 2018: (1) PubMed, (2) Scopus, (3) Web of Science, (4) Cochrane Central Register of Controlled Clinical Trials, (5) Embase, (6) google scholar, (7) clinical trials registry (ClinicalTrials.gov). In addition, cross-referencing from retrieved studies will be conducted. As publication bias caused by insufficient unpublished data can significantly bias the comparative efficacy results of network meta-analyses and modify rankings, we will also perform searches for unpublished or ongoing trials using the System for information on Grey Literature in Europe (SIGLE) as well as other registry platforms, such as Clinicaltrials.gov and the International Clinical Trials Registry Platform. Prior to completing this review, we will perform an additional search of each database and registration platform to guarantee that the most recent studies are included. Electronic databases will be searched for studies on the effects of drugs on risk factors safety in adults with MetS. The first author will conduct all database searches. The search strategy for all other databases will be adapted based on the requirements of each database. The search strategy will be developed by LR and HRZ; we anticipate that the databases will be searched from their inception to 30 December 2018, the search strategies for PubMed, EMBASE, Cochrane Library, Web of Science, Embase, google scholar, clinical trials registry (ClinicalTrials.gov).

Participants

Inclusion: The participants must be adults, aged at least 18 years, suffering from and requiring treatment pharmacology for EAT. Measurement of epicardial adipose tissue (EAT) by linear or volumetric analysis using MRI, CT or echocardiography. Patients who have undergone a full 3D assessment of the myocardium in order to obtain full volumetric measurement of the epicardial adipose tissue. This can only be performed with MRI or CT imaging. Echocardiography as an imaging modality to obtain myocardial function, specifically measures of systolic function (e.g. ejection fraction), diastolic function (e’, E/A ratio and other Doppler derived indices, as well as global longitudinal strain analysis), or full volume cardiac CT or MRI imaging to obtain ventricular volumes function parameters.

Exclusion: The participants suffering from other metabolic disease conditions or aged less than 18 years.

Interventions

Inclusion: Any RCT that evaluates the efficacy of these drugs.

Exclusion: Any RCT that evaluates other drugs or combined treatments of multiple drugs or placebo. We plan to include the following drugs: Simvastatin, Atorvastatin, Pravastatin, Rosuvastatin, Lovastatin, Fluvastatin, Pitavastatin, metformin, glimepiride, glyburide, glipizide, repaglinide, nateglinide, sitagliptin, vildagliptin, saxagliptin, SGLT-2 (sodium-glucose transporter-2) inhibitors, phentermine, topiramate,
lorcaserin, orlistat, fibrates, nicotinic acid, omega-3 fatty acids, and drugs from other classes [CCBs (calcium channel blockers), ARBs (angiotensin II receptor blockers), diuretics and ACEIs (angiotensin-converting enzyme inhibitors)]. In addition to these drugs, we will also obtain information about interventions of interest from either pairwise RCTs or placebo-controlled trials, as some RCTs design a placebo-controlled arm as the comparator.

Controls

**Inclusion:** Any RCT that evaluates the efficacy of these drugs other than the drug of intervention or placebo.

**Exclusion:** Any RCT that evaluates other drugs or combined treatments of multiple drugs.

Types of study

**Inclusion:** Only RCTs will be included.

**Exclusion:** Observational cohort and case–control studies, case reports, experimental studies and reviews will be excluded.

Other criteria

Other inclusion criteria: The RCTs must report complete efficacy data of risk factors of each treatment. Follow-up periods or durations in RCTs are at least 4 weeks. Other exclusion criteria are (1) duplicated or redundant studies and (2) combined treatments with multiple drugs.

Study selection

Reviewers will screen all titles or abstracts or full texts for database records independently according to the eligibility criteria. Disagreements between reviewers will be resolved by consensus. Selection process of relevant studies retrieved from databases will be shown in a PRISMA-compliant flow chart (Figure 1) [1-12].

Data extraction and quality assessment

Data of the study characteristics and the clinical outcome measures will be extracted. The data extracted from the RCTs are: (1) authors; (2) publication year; (3) baseline of outcome measures; (4) sample sizes; (5) interventions of both arms; (6) dosages of both arms and (7) treatment outcome measures including HbA1c and FPG. The data will be standardized and the quality of eligible studies will be evaluated according to the Cochrane Collaboration’s risk of bias tool for assessing risk of bias [13]. Radar chart (or star chart) will be used to summarize the results [14].

Outcomes

Outcome measures of drugs efficacy include mean changes of diagnostic of EAT and all-cause mortality (primary outcome) and risk factors, cardiovascular mortality, cancer mortality; cardiovascular incidence, and cancer incidence (secondary outcome) from baseline and their corresponding variation. Report the number of events, sample size, and follow-up time for each group, or report the hazard ratio with a measure of uncertainty or where there are sufficient details for this to be calculated (for example, from a confidence interval or P value). We will include the safety and efficacy assessment of drugs.

Statistical analysis

Pairwise meta-analysis of the included RCTs with random effect model due to the expected heterogeneity will be conducted [15-16].

---

**Figure 1. Flow diagram of study selection process**
Mean difference (MD) will be used to synthesis the continuous outcome data: mean changes from baseline of the risk factors in both arms. I² was used to estimate the heterogeneity. Networks will be generated to visualize the results of pairwise meta-analysis and the current evidence from the included RCTs [17].

NMA based on the Bayesian hierarchical model will be performed to compare the efficacy of selected drugs. Placebo will be used as common comparison in NMA [18]. Relative MD to the placebo will be output to assess the efficacy. The probability of each drug being ranked in each position based on risk factors will be computed [19]. Kendall’s test will be used to test the correlation between the relative MD and the ranking position.

Sensitivity analysis based on the sample size of the RCTs will be conducted when RCTs with sample size less than 50 are excluded. Sensitivity analysis will also be conducted on different baselines. Meta-regression analyses will be conducted on the different follow-up periods and dosages for the included RCTs. Begg’s and Egger’s tests will be used to evaluate the publication bias [20]. Agreement will be computed to assess the consistency between pairwise and network meta-analyses.

R software will be used to implement the analysis workflow. Package ‘metafor’ will be used to conduct pairwise meta-analysis. Package ‘igraph’ will be used to visualize the networks [21-24]. Package ‘fmsb’ will be used to visualize the results of risk of bias assessment. Package ‘gemtc’, ‘R2WinBUGS’ in R and WinBUGS will be used to conduct NAM. Package ‘ggplot2’ will be used to visualize the distribution of ranking probability distribution [25-31]. p Values lower than 0.05 will be considered statistically significant.

Assessment of risk of bias of included studies

Two reviewers will evaluate the risk of bias of the selected RCTs according to the criteria and technique proposed in the Cochrane Handbook V.5.1.0, which includes random sequence generation (selection bias), allocation concealment (selection bias), blinding of participants and personnel (performance bias), blinding of outcome assessment (detection bias), incomplete outcome data (attrition bias), selective reporting (reporting bias) and other bias. Each study will be assigned a level of risk of bias (high risk, unclear risk, low risk) for each item [21]. Any disagreement will be resolved through discussion or consultation with an independent third adjudicator.

Geometry of the network

A network plot will be drawn to present the geometry of the network of comparisons across trials to ensure a NMA is feasible. Trials will be excluded if they are not connected by interventions. Nodes in network geometry represent different interventions and edges represent head to head comparisons. The size of nodes and thickness of edges are associated with sample sizes and numbers of RCTs, respectively.

Heterogeneity

We will assess clinical and methodological heterogeneity through examination of the characteristics of the included trials. Heterogeneity across trials will be assessed by c² and I² statistics. If the P value is ≥0.1 and I² ≤50%, which suggests there is no statistical heterogeneity, then the Mantel–Haenszel fixed effects model will be employed. If the P value is <0.1 and I² >50%, we will explore sources of heterogeneity by subgroup analysis and meta-regression. If no clinical heterogeneity is identified, the Mantel–Haenszel random effects model will be used [32]. Publication bias will be examined using Begg’s and Egger’s funnel plot method when applicable [33-34]. In addition, the contour-enhanced funnel plot will be obtained as an aid to distinguish asymmetry due to publication bias [35-36].

Network meta-analysis

We will perform Bayesian NMAs with the package ‘gemtc’ V.0.8.1 of R-3.3.2 software to compare the effects of different prophylactic agents. The Markov Chains Monte Carlo sampler will be used to generate samples. A total of 5000 simulations for each chain will be set as the ‘burn-in’ period. Then, posterior summaries will be based on 100 000 subsequent simulations. Model convergence will be assessed using the Brooks–Gelman–Rubin plots method [37]. Global heterogeneity will be assessed on the bias of the magnitude of heterogeneity variance parameter (I² or τ²) estimated from the NMA models using the mtc. To rate the command of the ‘gemtc’ package, a node splitting method will be used to examine the inconsistency between direct and indirect comparisons when a loop connecting three arms exists [38]. The ranking probabilities for all treatments will be estimated, and a treatment hierarchy using the probability of being the best treatment can be obtained. This process will be performed using the cumulative ranking curve (SUCRA) [39]. SUCRA values are expressed as percentages—100% for the best treatment, 0% for the worst treatment. We will also try to use the frequentist approach to compare stability if necessary [40-41].

Assessment of the quality of evidence

The quality of evidence will be evaluated using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) using four levels: high quality, moderate quality, low quality and very low quality [42]. This process will be performed with the online guideline development tool (GDT, http://gdt.guidelinedevelopment.org/).

Meta-regression

In case there is significant heterogeneity and inconsistency, we will use meta-regression to explain the heterogeneity, provided we have enough data to do so; otherwise, we will perform subgroup analyses. We will perform meta-regression using study level covariates: methodological quality (high risk of bias versus low risk of bias), participant’s average age, Body mass index (BMI) status (obese and/or overweight BMI ≥25 kg/m² versus normal <25 kg/m²), homeostatic model assessment (HOMA-IR) (high and moderate ≥3 versus low <3), medication dose, length of treatment (≥3 months versus <3 months). We will also perform a subgroup analysis to assess the efficacy of different oral formulations to verify changes in MetS risk factors.

Rating the confidence in estimates of the effect in NMA

The confidence in the estimates (quality of evidence) for each reported outcome will be assessed independently by two reviewers (LR, FCV) using the Grading of Recommendations Assessment, Development, and Evaluation Working Group (GRADE Working Group) approach; for the flow of quality assessment [43]. The quality of evidence is categorized by GRADE into four levels: high quality, moderate quality, low quality, and very low quality. For the direct comparisons, we will assess and rate each outcome based on the five GRADE categories: risk of bias, imprecision, inconsistency, indirectness, and publication bias [44]. For the assessment of confidence in the estimates obtained in the NMA, we will use the recent approach recommended by the GRADE working group [45]. We will assess and rate the confidence in all the indirect comparisons, if available, obtained from first order
loops following the five GRADE categories used for assessing the direct comparisons in addition to the intratreatment assessment. Then, we will rate the confidence in each NMA effect estimate using the higher quality rating when both direct and indirect evidence are present. However, the estimate can be rated down for irrelevance [46].

References

1. Basuato Avezvedo L, Barrera Hernández S, Fernández Muñoz MJ, Sáucedo García RP, Rodríguez Luna AK, et al. (2018) An increase in epicardial fat in women is associated with thrombotic risk. Clin Invest Arterioscler. [Crossref]
2. Oliveira GBF, Avezum A, Roever L (2015) Cardiovascular disease burden: evolving knowledge of risk factors in myocardial infarction and stroke through population-based research and perspectives in global prevention. Front Cardiovasc Med 2: 32. [Crossref]
3. Roever L, Biondi-Zoccai G, Chagas AC (2016) Non-HDL-C vs. LDL-C in Predicting Adiposopathy and association with cardiovascular disease risk factors: The Uberlândia Heart Study. Medicine (Baltimore) 95: e1357. [Crossref]
4. Roever L, Resende ES, Diniz AL, Penha-Silva N, Veloso FC, et al. (2016) Abdominal Obesity and Association With Adiposopathy Risk Factors: The Uberlândia Heart Study. Medicine (Baltimore) 95: 25: 953-954. [Crossref]
5. Roever L, Resende ES, Diniz AL, Penha-Silva N, Veloso FC, et al. (2015) Ecopic adiposopathy and association with cardiovascular disease risk factors: The Uberlândia Heart Study. Int J Cardiol 190: 140-142. [Crossref]
6. Roever L, Resende ES, Veloso FC, Diniz AL, Penha-Silva N, et al. (2015) Perinatal Fat and Association With Metabolic Risk Factors: The Uberlândia Heart Study. Medicine (Baltimore) 94: e1105. [Crossref]
7. Ven Rooy MJ (2015) Preterius E: Metabolic syndrome, platelet activation and the development of transient ischemic attack or thromboembolic stroke. Thromb Res 135: 434-442. [Crossref]
8. Sarráf Zadegan N, Gharipour M, Sadeghi M, Nezafati P, Taleie M, et al. (2017) Metabolic Syndrome and the Risk of Ischemic Stroke. J Stroke Cerebrovasc Dis 26: 286-294. [Crossref]
9. Sánchez-Itilgo L, Navarro-González D, Fernández-Montero A, Pastrana-Delgado J, Martínez JA (2017) Risk of incident ischemic stroke according to the metabolic health and obesity states in the Vascular-Metabolic CUN cohort. Int J Cardiol 190: 140-142. [Crossref]
10. Paez AR, Landefeld D, Foodman L, DuBois D, Jee J, et al. (2001) Metabolic Syndrome and its Components. and Diabetes and obesity states in the Vascular-Metabolic CUN cohort. Int J Cardiol 190: 140-142. [Crossref]
11. Chei CL, Yamagishi K, Tanigawa T, Kitamura A, Imano H, et al. (2008) Metabolic Syndrome, and the Risk of Ischemic Heart Disease and Stroke among Middle-Aged Japanese. Hypertens Res 31: 1887-1889. [Crossref]
12. Fang X, Liu H, Zhang X, Zhang H, Qin X, et al. (2016) Adiposopathy, and obesity states in the Vascular-Metabolic CUN cohort. Int J Cardiol 190: 140-142. [Crossref]
13. Schwamm LH, Feinberg WM, Hlatky MA, et al. (2006) The Igraph software package for complex network research. Inter J Complex Syst 1095.
14. Nakazawa M (2014) Functions for medical statistics book with some demographic data. R package Version 0.6-5, 2014.
15. van Valkenhoef G, Lu G, de Brock B, Hillege H, Ades AE, et al. (2012) Automating network meta-analysis. Res Synth Methods 3: 285-298. [Crossref]
16. Sturtz S, Ligges U, Gelman A (2005) A package for running WinBUGS from R. J Stat Softw 12: 1-16.
17. Lunn DJ, Thomas A, Best N, Spiegelhalter D (2000) WinBUGS—a Bayesian modelling framework: concepts, structure, and extensibility. Stat Comput 10: 325-333.
18. Wickham H (2009) ggplot2: Elegant Graphics for Data Analysis. Springer.
19. Jia Y, Lao Y, Leung SW (2015) Glycemic control efficacy of oral antidiabetic drugs in treating type 2 diabetes: a protocol for network meta-analysis. BMJ Open 5: e006319. [Crossref]
20. Higgins JPT GS, Cochrance handbook for systematic reviews of interventions version 5.11[EB/OL]. The Cochrane Collaboration, 2011. http://www.cochrane-handbook.org
21. Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50: 1088-1101. [Crossref]
22. Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629-634. [Crossref]
23. Peters JL, Sutton AJ, Jones DR, et al. Contour-enhanced metaanalysis funnel plots help distinguish publication bias from other causes of asymmetry. J Clin Epidemiol 61: 991-996. [Crossref]
24. van Valkenhoef G, Kuiper J (2017) gemtc: network meta-analysis using Bayesian methods. https://rdrr.io/cran/gemtc/
25. Wu HY, Huang JW, Lin HJ, Liao WC, Peng YS, et al. (2013) Comparative effectiveness of renin-angiotensin system blockers and other antihypertensive drugs in patients with diabetes: systematic review and bayesian network meta-analysis. BMJ 347: 68008. [Crossref]
26. Lu G, Ades AE (2004) Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med 23: 3105-3124. [Crossref]
27. Salanti G, Ades AE, Ioannidis JP (2011) Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol 64: 163-171. [Crossref]
28. Hoaglin DC, Hawkins N, Jansen JP, Scott DA, Itzler R, et al. (2011) Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 2. Value Health 14: 429-437. [Crossref]
29. Comparing bayesian and frequentist approaches for network metaanalysis: An empirical study.
30. Puhan MA, Schünemann HJ, Murad MI, Li T, Brigandello-Petersen R, et al. (2014) A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis. BMJ 349: g5630. [Crossref]
31. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, et al. (2011) GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol 64: 163-171. [Crossref]
32. Puhan MA, Schünemann HJ, Murad MI, Li T, Brigandello-Petersen R, et al. (2014) A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis. BMJ 349: g5630. [Crossref]
45. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, et al. (2011) GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol 64: 383-394.

46. Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, et al. (2011) GRADE guidelines: 8. Rating the quality of evidence-indirectness. J Clin Epidemiol 64: 1303-1310. [Crossref]